Pharma BD Deal Intelligence
A failed bet, not a mixed one: Gilead's filgotinib collaboration ended in an FDA rejection, a second Phase 3 flop (ziritaxestat), and Gilead abandoning the franchise entirely—Galapagos sold the drug to Alfasigma in 2024 while Gilead still sits on a marked-down equity stake with no blockbuster to show for it.
Filgotinib's Phase 2 RA data drove the Gilead partnership, though a single DVT case foreshadowed the JAK class-wide thrombosis safety concerns that would…
Gilead returned filgotinib rights to Galapagos in late 2020, marking a clear failure of the 2015 collaboration's US thesis and a setback for CEO O'Day's…
Filgotinib received first approval in Japan/EU as Jyseleca for RA in 2020, validating the JAK1-selective mechanism in ex-US markets despite the FDA setback.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Gilead and Galapagos closed their global license and collaboration for filgotinib, a selective JAK1 inhibitor in Phase 3 for rheumatoid arthritis. Galapagos received $725M upfront ($300M license fee + $425M equity investment giving Gilead 14.75% stake at EUR58/share). Galapagos eligible for up to $1.35B in milestones plus tiered royalties starting at 20%, with co-promotion profit splits in select territories.
Assessment window: 5yr post-close.
$128.0B US RA medical + indirect annual cost
Rheumatoid arthritis is a chronic systemic autoimmune disease characterized by symmetric polyarticular synovitis, joint destruction, and extra-articular manifestations affecting roughly 1.3 million US adults. Despite the success of TNF inhibitors and IL-6 blockers, 30-40% of patients fail to achieve sustained remission, driving demand for orally-dosed targeted synthetic DMARDs such as JAK inhibitors.
When Gilead and Galapagos closed the filgotinib deal in January 2016, the RA market was dominated by AbbVie's Humira (adalimumab), J&J/Merck's Remicade (infliximab), and Roche's Actemra (tocilizumab), with Pfizer's Xeljanz (tofacitinib) representing the only approved oral JAK inhibitor in the US. Filgotinib (GLPG0634) was positioned as a JAK1-selective inhibitor — theoretically offering a cleaner safety profile than pan-JAK Xeljanz by avoiding JAK2/JAK3-mediated cytopenia and infection risk. Lilly's baricitinib (Olumiant, JAK1/JAK2) was also racing through Phase 3. The deal gave Gilead a $725M upfront-priced ($300M license + $425M equity at €58/share) bet on a non-HCV growth pillar at a time when HCV revenue was beginning its decline. Filgotinib delivered Phase 3 wins (FINCH program) and was approved in EU/Japan as Jyseleca in 2020, but the FDA rejected the US application in August 2020 over male reproductive toxicity concerns, leading Gilead to gut its filgotinib plans and ultimately return rights to Galapagos in late 2020 — a widely-cited example of partnership risk in the JAK class after the FDA's class-wide black box on cardiovascular and malignancy events.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Galapagos NV (this deal) | 2016 | $2.1B | 19 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2016 deals · Gilead Sciences Inc. deals · Gastroenterology deals